SmithKline And SBL Vaccine Agreement

6 February 1995

SmithKline Beecham and Swedish Bacteriological Laboratories (SBL Vaccin AB) have signed an agreement to develop and commercialize vaccines to protect against diarrhoea caused by enterotoxigenic Escherichia coli and cholera.

Under the terms of the agreement, SBL will develop and manufacture the vaccines. SmithKline Beecham will register and market the vaccines on a worldwide basis except in the Nordic countries and the Baltics, where SBL will retain marketing rights.

Clinical studies to date with the oral cholera vaccine, reports SKB, have shown that it provides superior protection to currently available injectable vaccines and demonstrates high immunogenicity with a very low adverse event profile.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight